IHS Chemical Week

EnviroTech :: Biotech

BPA: Brisbane Facility to Bridge Infrastructure Gap in Australia’s Biotechnology Manufacturing Chain

12:59 AM MDT | May 26, 2010 | Deepti Ramesh

BioPharmaceuticals Australia (BPA; Brisbane) tells CW that the total investment involved in constructing the previously announced mammalian biopharmaceutical manufacturing facility at Brisbane, Australia would be about A$61 million ($51 million). DSM Biologics, a DSM subsidiary, announced earlier this month that it had entered into a partnership with state and local authorities in Australia to build and operate the mammalian biopharmaceutical manufacturing facility at Brisbane. The Queensland and Australian governments will provide full financial funding for the...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa